A trial fibrillation (AF), the most common chronic cardiac arrhythmia, is an increasingly significant source of morbidity, mortality, and public health concern in the United States. It currently affects 2.2 million Americans, but its prevalence is projected to rise to 12 million by 2050 (Vasan, Benjamin, Sullivan, & D'Agostino, 2008 ). An analysis of data from the Framingham Heart Study found that the lifetime risk at age 40 of developing AF was 23% for women and 26% for men, with incidence rising with age (Lloyd-Jones, et al., 2004) . AF is a risk factor for worsened quality of life, embolic stroke, congestive heart failure, and death.
Electrophysiologically, AF is characterized by uncoordinated electrical activity in the atria, suspected to be triggered by ectopic beats originating at the junction of the left atrium and the pulmonary veins. Ventricular response can be either fast or slow. Electrocardiography shows irregularly irregular R-R intervals and an absence of P waves.
Reversion of AF to normal sinus rhythm can be achieved using either electrical cardioversion or chemical cardioversion via antiarrhythmic medications. However, long-term maintenance of sinus rhythm can be difficult to achieve in many individuals. Two main treatment options are available: chronic antiarrhythmic drug therapy and radiofrequency catheter ablation. Pharmacologic antiarrhythmic agents remain the first-line therapy for AF because of their ease of use, but their variable effectiveness and sometimes serious side effects have led to growing interest in radiofrequency catheter ablation.
Although ablation is a relatively new treatment, evidence of its efficacy is accumulating. A recent randomized trial compared catheter ablation with antiarrhythmic drug therapy for symptomatic AF. By the end of the 9-month evaluation period, 66% of the individuals who had undergone ablation remained AF-free, whereas only 16% of the individuals who had received pharmacologic therapy remained AFfree. Furthermore, the incidence of treatment-related adverse events was lower in the ablation group (4.9%) than in the antiarrhythmic drug therapy group (8.8%) (Wilber et al., 2010) . A longer-term study demonstrated greater improvements in morbidity and mortality rates and quality of life for ablation patients compared with patients on antiarrhythmic drug therapy (Pappone et al., 2003) .
Radiofrequency catheter ablation is an inpatient procedure performed under conscious sedation. Catheters are introduced via the femoral veins and advanced superiorly into the right side of the heart; the left atrium is accessed by crossing the interatrial septum. Finally, radiofrequency waves are used to selectively destroy atrial tissue thought to be responsible for triggering and maintaining AF. In the most common form of ablation, the tissue targeted for destruction is around the pulmonary veins' entrance into the left atrium. After the ablation, the tissue is unable to trigger or conduct electrical impulses outside of the heart's normal pacing and conduction pathways. Thus, the recurrence of AF is prevented. The individual remains in the hospital overnight following the ablation. Some of the potential complications of the procedure include embolic stroke, pulmonary embolism, atrioesophageal fistula, heart block, and death.
From an occupational health perspective, the most important consideration is risk of bleeding. Postoperatively, anticoagulation (typically warfarin) will be required for 3 months. During the first week postoperatively, strenuous activity and heavy lifting are contraindicated to prevent bleeding at the sites of catheter insertion. Following the individual's return to the workplace, precautions must be taken as they would for any individual receiving long-term anticoagulation. Monitoring must be conducted for a therapeutic International Normalized Ratio level. The individual must avoid situations that increase the risk of head trauma and subsequent intracranial hemorrhage.
